Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARγ

Cancer Research

Volumn 65, Issue 4, 2005, Pages 1561-1569

  Shiau, Chung Wai ^a   Yang, Chih Cheng ^a   Kulp, Samuel K ^a   Chen, Kuen Feng ^a   Chen, Chang Shi ^a   Huang, Jui Wen ^a   Chen, Ching Shih ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 [4 (1 METHYLCYCLOHEXYLMETHOXY)BENZYLIDENE]THIAZOLIDINE 2,4 DIONE; 5 [4 (6 HYDROXY 2,5,7,8 TETRAMETHYLCHROMAN 2 YLMETHOXY)BENZYLIDENE] 2,4 THIAZOLIDINE DIONE; 5 [4 [2 (5 ETHYLPYRIDIN 2 YL)ETHOXY]BENZYLIDINE]THIAZOLIDINE 2,4 DIONE; 5 [4 [2 (METHYLPYRIDIN 2 YLAMINO)ETHOXY]BENZYLIDENE]THIAZOLIDINE 2,4 DIONE; CIGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROTEIN BAK; PROTEIN BCL 2; PROTEIN BCL XL; ROSIGLITAZONE; TG 88; THIAZOLE DERIVATIVE; TROGLITAZONE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; HUMAN; HUMAN CELL; IN VIVO STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR UPREGULATION;

ANIMALS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-X PROTEIN; CHROMANS; HUMANS; MALE; MEMBRANE PROTEINS; MICE; MICE, NUDE; PPAR GAMMA; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-BCL-2; THIAZOLIDINEDIONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 13944280963     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1677     Document Type: Article

References (36)

1. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 1999;16:179-92.
2. Koeffler HP. Peroxisome proliferator-activated receptor γ and cancers. Clin Cancer Res 2003;9:1-9.
3. Tontonoz P, Singer S, Forman BM, et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc Natl Acad Sci U S A 1997;94:237-41.
4. Gupta RA, Brockman JA, Sarraf P, Willson TM, DuBois RN. Target genes of peroxisome proliferator-activated receptor γ in colorectal cancer cells. J Biol Chem 2001;276:29681-7.
5. Altiok S, Xu M, Spiegelman BM. PPARγ induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev 1997;11:1987-98.
6. Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM, Halperin JA. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γ and mediated by inhibition of translation initiation. Cancer Res 2001;61:6213-8.
7. Takeda K, Ichiki T, Tokunou T, lino N, Takeshita A. 15-Deoxy-δ 12,14-prostaglandin J2 and thiazolidine-diones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells. J Biol Chem 2001;276:48950-5.
8. Gouni-Berthold I, Berthold HK, Weber AA, et al. Troglitazone and rosiglitazone induce apoptosis of vascular smooth muscle cells through an extracellular signal-regulated kinase-independent pathway. Naunyn Schmiedebergs Arch Pharmacol 2001;363:215-21.
9. Bae MA, Song BJ. Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells. Mol Pharmacol 2003;63:401-8.
10. Baek SJ, Wilson LC, Hsi LC, Eling TE. Troglitazone, a peroxisome proliferator-activated receptor γ (PPAR γ) ligand, selectively induces the early growth response-1 gene independently of PPAR γ. A novel mechanism for its anti-tumorigenic activity. J Biol Chem 2003;278:5845-53.
11. Motomura W, Okumura T, Takahashi N, Obara T, Kohgo Y. Activation of peroxisome proliferator-activated receptor γ by troglitazone inhibits cell growth through the increase of p27KiP1 in human pancreatic carcinoma cells. Cancer Res 2000;60:5558-64.
12. Sugimura A, Kiriyama Y, Nochi H, et al. Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor. Biochem Biophys Res Commun 1999;261:833-7.
13. Okura T, Nakamura M, Takata Y, Watanabe S, Kitami Y, Hiwada K. Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells. Eur J Pharmacol 2000;407:227-35.
14. Elstner E, Muller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998;95:8806-11.
15. Mueller E, Smith M, Sarraf P, et al. Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer. Proc Natl Acad Sci U S A 2000;97:10990-5.
16. Yang CC, Lin HP, Chen CS, Yang YT, Tseng PH, Rangnekar VM. Bcl-xL mediates a survival mechanism independent of the phosphoinositide 3-kinase/Akt pathway in prostate cancer cells. J Biol Chem 2003;278:25872-8.
17. Dandliker WB, Hsu ML, Levin J, Rao BR. Equilibrium and kinetic inhibition assays based upon fluorescence polarization. Methods Enzymol 1981;74(Pt C):3-28.
18. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
19. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-δ 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR γ. Cell 1995;83:803-12.
20. Wang JL, Liu D, Zhang ZJ, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A 2000;97:7124-9.
21. Degterev A, Lugovskoy A, Cardone M, et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol 2001;3:173-82.
22. Tzung SP, Kim KM, Basanez G, et al. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol 2001;3:183-91.
23. Enyedy IJ, Ling Y, Nacro K, et al. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem 2001;44:4313-24.
24. Lugovskoy AA, Degterev AJ, Fahmy AF, et al. A novel approach for characterizing protein ligand complexes: molecular basis for specificity of small-molecule Bcl-2 inhibitors. J Am Chem Soc 2002;124:1234-40.
25. Chan SL, Lee MC, Tan KO, et al. Identification of chelerythrine as an inhibitor of BclXL function. J Biol Chem 2003;278:20453-6.
26. Zhang M, Liu H, Guo R, et al. Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem Pharmacol 2003;66:93-103.
27. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003;22:8590-607.
28. Sattler M, Liang H, Nettesheim D, et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997;275:983-6.
29. Diaz JL, Oltersdorf T, Home W, et al. A common binding site mediates heterodimerization and homodimerization of Bcl-2 family members. J Biol Chem 1997;272:11350-5.
30. Otter I, Conus S, Ravn U, et al. The binding properties and biological activities of Bcl-2 and Bax in cells exposed to apoptotic stimuli. J Biol Chem 1998;273:6110-20.
31. Nouraini S, Six E, Matsuyama S, Krajewski S, Reed JC. The putative pore-forming domain of Bax regulates mitochondrial localization and interaction with Bcl-X(L). Mol Cell Biol 2000;20:1604-15.
32. Finnegan NM, Curtin JF, Prevost G, Morgan B, Cotter TG. Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bcl-2 interactions. Br J Cancer 2001;85:115-21.
33. Kubota T, Koshizuka K, Williamson EA, et al. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998;58:3344-52.
34. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med 1998;4:1046-52.
35. Lefebvre AM, Chen I, Desreumaux P, et al. Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/ 6J-APCMin/+ mice. Nat Med 1998;4:1053-7.
36. Saez E, Tontonoz P, Nelson MC, et al. Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nat Med 1998;4:1058-61.